key: cord-0984389-bmkcu2gl
authors: Kastora, Stavroula; Patel, Manisha; Carter, Ben; Delibegovic, Mirela; Myint, Phyo Kyaw
title: Impact of diabetes on COVID‐19 mortality and hospital outcomes from a global perspective: An umbrella systematic review and meta‐analysis
date: 2022-04-20
journal: Endocrinol Diabetes Metab
DOI: 10.1002/edm2.338
sha: 274138865801132547c2d934936b54333c48a801
doc_id: 984389
cord_uid: bmkcu2gl

INTRODUCTION: To date, COVID‐19 has claimed 4.9 million lives. Diabetes has been identified as an independent risk factor of serious outcomes in people with COVID‐19 infection. Whether that holds true across world regions uniformly has not been previously assessed. METHODS: This study offers the first umbrella systematic review and meta‐analysis to analyse the collective and geographically stratified mortality, ICU admission, ventilation requirement, illness severity and discharge rate amongst patients with diabetes. Five databases (EMBASE, MEDLINE, CAB Abstracts, PsychInfo and Web of Science) and 3 additional sources (SSRN's eLibrary, Research Square and MedRxiv) were searched from inception to 30 August 2021. Prospective and retrospective cohort studies, reporting the association between diabetes and one or more COVID‐19 hospitalization outcomes, were included. This meta‐analysis was registered on PROSPERO, CRD42021278579. Abbreviated MeSH terms used for search were as follows: (Diabetes) AND (2019 Novel Coronavirus Disease), adapted per database requirements. Exclusion criteria exclusion criteria were as follows: (1) none of the primary or secondary outcomes of meta‐analysis reported, (2) no confirmed COVID‐19 infection (laboratory or clinical) and (3) no unexposed population (solely patients with diabetes included). Quality of the included studies were assessed using the Newcastle‐Ottawa Scale (NOS) whilst quality of evidence by the GRADE framework. Studies that were clinically homogeneous were pooled. Summative data and heterogeneity were generated by the Cochrane platform RevMan (V. 5.4). RESULTS: Overall, 158 observational studies were included, with a total of 270,212 of participants, median age 59 [53–65 IQR] of who 56.5% were male. A total of 22 studies originated from EU, 90 from Far East, 16 from Middle East and 30 from America. Data were synthesized with mixed heterogeneity across outcomes. Pooled results highlighted those patients with diabetes were at a higher risk of COVID‐19‐related mortality, OR 1.87 [95%CI 1.61, 2.17]. ICU admissions increased across all studies for patients with diabetes, OR 1.59 [95%CI 1.15, 2.18], a result that was mainly skewed by Far East‐originating studies, OR 1.94 [95%CI 1.51, 2.49]. Ventilation requirements were also increased amongst patients with diabetes worldwide, OR 1.44 [95%CI 1.20, 1.73] as well as their presentation with severe or critical condition, OR 2.88 [95%CI 2.29, 3.63]. HbA1C levels under <70 mmol and metformin use constituted protective factors in view of COVID‐19 mortality, whilst the inverse was true for concurrent insulin use. CONCLUSIONS: Whilst diabetes constitutes a poor prognosticator for various COVID‐19 infection outcomes, variability across world regions is significant and may skew overall trends.

COVID-19, a novel coronavirus identified in late 2019, has rapidly spread worldwide resulting in the first pandemic experienced in the modern world since 1918. 1 Currently, more than 220 million have been infected, with 4.9 million deaths as of 18 October 2021.

Metabolic conditions, and primarily diabetes, have emerged since the beginning of the pandemic as significant risk factors for poor COVID-19 outcomes. 2 A wealth of observational studies and consequently meta-analyses have attempted to quantify the association of diabetes as an independent risk factor of poor COVID-19 outcomes and consistently found that diabetes is associated with poorer outcomes across this patient group.

Until present and to the best of our knowledge, an umbrella systematic review and meta-analysis has not been conducted to collectively assess available meta-analyses. Furthermore, whilst patient ethnicity as well as global discrepancies of healthcare facilities and antidiabetic medication access are well-established variables, [3] [4] [5] [6] [7] no previous work has factored in, study geographical origin to assess the potential impact of these parameters on COVID-19 outcomes in patients with diabetes.

We primarily aim to quantify the overall impact of diabetes in COVID-19 across three main outcomes: mortality, ICU admission and ventilation (invasive and non-invasive). Secondary outcomes include illness severity, discharge rate, identification of putative geographical variability across outcomes and associated factors of poorer or improved prognosis, amongst patients with diabetes. Infection OR SARS-CoV-2 Infection).mp. limit to (English language and humans). The same search strategy was adapted for the remaining databases.

Prospective and retrospective cohort studies were extracted from eligible systematic reviews and meta-analyses to enable umbrella systematic review of available data as described in Aromataris et al., 8 examining COVID-19 mortality, ICU admission, ventilation requirement, disease severity and discharge in the context of diabetes (Table S1) .

Restrictions included English language and human. After removing duplicates (EndNote V.20), citations were screened by title and abstract; then, full texts were appraised to determine their eligibility by two authors (SK and MP) ( Figure 2 ). Two authors (SK and MP) independently conducted the abstract and full-text screening. Disagreements were resolved by a consensus meeting. Peer-reviewed full-text papers that reported one or more of the primary outcomes were selected. Full-text exclusion criteria were as follows: (1) none of the primary or secondary outcomes of meta-analysis reported, (2) Quality of the included studies were assessed by two independent reviewers (SK and MP) using the Newcastle-Ottawa Scale (NOS) for observational studies. 9 Studies were of high quality if a NOS score ≥6 was achieved. 10 Adequate follow-up was ≥30 days (Table S1 ). Overall grading the quality of evidence was assessed by the GRADE framework. 11 Heterogeneity was assessed using I 2 .

Study primary outcomes included mortality, ICU admission and ventilation requirement events. These were defined as the proportion of people with an event, of each respective outcome, in comparison to people without the event, in the same population. Secondary outcomes were disease severity [mild, moderate and severe/critical] (events) and discharge events amongst patients with diabetes vs. adjusted HRs were presented with associated 95% confidence intervals (CI) ( Figure S3 ). For crude HRs, antidiabetic medication brand, dose and duration of action were not possible to factor in, due to lack of data reporting in individual studies. Adjusted HR (95% CI) of mortality amongst patients with diabetes was adjusted for age, gender, cardiovascular comorbidities, biochemical findings, smoking/alcohol use, immunocompromised status and medications ( Figure S4 ). (Table S1) . with shock or respiratory failure, mechanical ventilation requirement, or combined with other organ failure, requiring admission to intensive care unit (ICU). Individual severity definition per study is presented in Table S1.

Clinical context and design were compared and where appraised as homogeneous, studies were considered as suitable for pooling. 14 The meta-analysis was conducted by computing the pooled odds ratio (OR) as per Haensel-Mantel model or Hazard ratio (HR) as per inverse variance analysis, random effects (RE) with Review Manager (RevMan) V 5.4 software. Statistical heterogeneity was quantified using I 2 statistics and Cochrane Q tests.

Only studies that are clinically homogeneous were pooled.

Heterogeneity was assessed using I 2 , and I 2 greater than 70% was explored using subgroups. 14 The following subgroups were used to explain the heterogeneity: risk of bias; age, geography, study design (prospective). Asymmetry was assessed by funnel plot, and asymmetry was assessed formally by rank correlation test (Begg's test;

RevMan V. 5.4). Sensitivity analyses were conducted to assess the impact of individual potential confounding variables. Publication bias was assessed visually by funnel plot, and asymmetry was formally assessed, by rank correlation test (Begg's test). 15 

Following the PRISMA guidelines on systematic review search, we identified 53 eligible meta-analyses studies for study extraction. Post-individual study extraction and duplicate study removal, we identified 185 studies eligible for full-text screening ( Figure 2 ).

Full-text screening excluded 27 studies (Table S1) Table S1 ). 16 

We (SLK and MP) employed the NOS for quality assessment. 9

Ninety-nine (99) studies were graded as good, forty-two (42) as fair and eighteen (18) studies as poor according to independent grading as per NOS selection, comparability and outcome parameters (Table S1 ). Overall quality of evidence was assessed with the GRADE framework and was found to be high (Table S1 ). 11

A total of 136 studies were included in the analysis of mortality as an outcome ( Figure 3A ; Figure S2A , Table S1 ). Overall, studies supported the previously reported increased mortality in patients with diabetes, Table S1 ).

Mortality was explored amongst patients with type 1 vs. type 2 diabetes. Only two studies 82, 117 reported crude numbers of patients with type 1 or type 2 diabetes deaths, suggesting that patients with type 2 diabetes had worse outcomes in respect to mortality, OR 0.68 [95% CI 0.24, 1.87], I 2 = 0%. albeit the lack of statistical significance, possibly due to the limited sample size (p = .45, N: 308) ( Figure S3D ).

A total of 59 studies were included in the analysis of ICU admission as an outcome ( Figure 3B ; Table S1 ). Overall, studies supported and American studies did not reach statistical significance for this outcome ( Figure 3B ).

A total of 83 studies were included in the analysis of ventilation requirement as an outcome amongst patients with diabetes vs. without ( Figure 4A , Table S1 ). Overall, studies supported the previ- Table S1 ). Of note, American studies indicated a decrease of ventilation requirement in patients with diabetes, albeit the lack of statistical significance.

A total of 43 studies were included in the analysis of disease severity (severe or critical) as an outcome amongst patients with diabetes vs. without ( Figure 4B ; Figure S2D , Table S1 ). Overall, studies indicated increased patient numbers with diabetes pre- 

given that only one study reported this outcome. 105 

We sought to identify confounding factors that may correlate with COVID-19 mortality across included studies ( Figure S3 ). Overall, age over 65 years, HR 3.27 [2.83, 3.77] , p < .0001 ( Figure S3A) , 58, 157, 172 HbA1C over 70 

Whilst overall patient mortality has decreased since the beginning of the pandemic, attributable to variable clinical and non-clinical factors, metabolic conditions, amongst which diabetes, have emerged as significant risk factors for poor COVID-19 outcomes. 2 The present work is the first systematic review to assess outcomes of patients with diabetes in the context of COVID-19 infection whilst accounting for geographical location of outcome reports.

Overall, our findings indicate that patients with diabetes are at a higher risk of poor hospitalization outcomes, and this is stratified by geographical region. Whilst studies originating from the Far and Middle East reported statistically significant, higher mortality across patients with diabetes, this finding was not the case for the EU, or America world regions ( Table 1) . Whether healthcare and affordable F I G U R E 4 Odds associated with an increased ventilation (invasive and non-invasive) requirement in patients with diabetes (A) and patients with diabetes presenting with severe or critical condition (B). Haensel-Mantel statistical method with odds ratio (random effects) as output only for included observational studies and subgroups as per subgroup title. Summative forest plots of included observational studies of the meta-analysis (patients with Diabetes vs. without representing those with increased ventilation requirement (A) or those presenting with severe or critical illness (B) as per patient population. Illness severity definitions per included study are as presented in Table S1 . Forrest and associated funnel plots ( Figure S2C ,D) were generated with Review Manager V. 5.4 Cochrane Tool for meta-analysis antidiabetic medication access inequalities or whether inherent nonmodifiable (such as genetic variants) and modifiable parameters (such as obesity) across ethnic groups are responsible for this data variability, should be considered. [3] [4] [5] [6] [7] Furthermore, whilst geographical stratification did not lead to significant differences amongst world regions regarding disease severity in patients with diabetes, the need for ventilation, here defined as either invasive or non-invasive, was variable across the world. Studies from America, mostly reflecting USA trends, did not indicate higher ventilation requirements in this patient group. Whether this finding reflects overall healthcare system preparedness for catastrophic events, including pandemic emergence is not clear. 173 The present work has also highlighted those patients with overall better control of diabetes and on oral glucose-lowering medications such as metformin, had significantly improved outcomes in terms of mortality. Intriguingly, insulin use has been identified as a risk factor in COVID-19-positive, patients with diabetes. As almost the entirety of the patients with diabetes included in the present study, were patients with type 2 diabetes and given that insulin use is the final step in the control of type 2 diabetes, this finding may signify an overall decreased patient physiological reserve or poorer all-mortality outcomes, as shown in previous studies. 174 Whilst adjusted hazard ratios for medications amongst patients with diabetes still highlighted an increased risk of death in this patient group, biochemical variables including HbA1C where not consistently reported across studies to enable its inclusion in our adjusted model. Previous work has highlighted that hyperglycaemia in COVID-19 patients is notable (reviewed in Accili, 2021) . 175 Thus, the literature consensus, in agreement with our findings, supports that good glycaemic control is the best way prevent COVID-19-related admissions. 175 The lack of consistent evidence across studies did not allow for robust comparison of mortality outcomes amongst the patients with type 1 vs. F I G U R E 5 Odds associated with patient discharge at the end-of study follow-up. Haensel-Mantel statistical method with odds ratio (random effects) as output only for included observational studies and subgroups as per subgroup title. Summative forest plot of included observational studies of the meta-analysis (patients with Diabetes vs. without) representing respective discharge odds between the two populations. Forrest and associated funnel plots ( Figure S2E) 

To the best of our knowledge, the present work is the first umbrella meta-analysis and systematic review, to assess patients with diabetes outcomes regarding COVID-19 infection whilst accounting for geographical location of outcome reports. We have identified and addressed sources of heterogeneity by geographical and study design subgrouping sensitivity and IVR analysis. This study is the first to highlight major worldwide discrepancies and data variability worldwide in major clinical outcomes. Through this work, we highlight the overall healthcare system preparedness, medication availability and patient ethnicity-related modifiable and non-modifiable variables as putative risk factors of worldwide mortality, ICU and ventilation requirements, amongst the patients with diabetes.

Whilst diabetes is undoubtably a poor prognosticator of COVID-19

infection outcomes, geographical variations across world regions are notable. Whether this finding comes as a result of the variability of healthcare provisions for control and management or patient ethnicity remains to be fully elucidated.

The authors have no conflict of interest to declare.

Stavroula Kastora:Conceptualization (lead); data curation (lead);

formal analysis (lead); methodology (supporting); visualization (lead);

writing -original draft (lead); writing -review and editing (lead). 

The data used and analysed during the current study are available as online Supplementary Material.

Stavroula Kastora https://orcid.org/0000-0003-4470-5267

Phyo Kyaw Myint https://orcid.org/0000-0003-3852-6158

WHO Director-General's remarks at the media briefing on 2019-nCoV on 11

COVID-19 alters thinking and management in metabolic diseases

Inequalities in the global burden of chronic kidney disease due to type 2 diabetes mellitus: an analysis of trends from 1990 to 2019

Inequality in the treatment of diabetes and hypertension across residency status in China

A global perspective on the issue of access to insulin

Incremental risk of developing severe COVID-19 among Mexican patients with diabetes attributed to social and health care access disadvantages

Addressing racial and ethnic disparities in COVID-19 among school-aged children: are we doing enough?

Summarizing systematic reviews: methodological development, conduct and reporting of an umbrella review approach

The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. Ottawa Hospital Research Institute

Newcastle-Ottawa scale: comparing reviewers' to authors' assessments

GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables

Diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 7)

Train ing.cochr ane

Operating characteristics of a rank correlation test for publication bias

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan

Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series

Predictors of mortality in adults admitted with COVID-19: retrospective cohort study from New York City

The risk of diabetes on clinical outcomes in patients with coronavirus disease 2019: a retrospective cohort study

Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study

Characteristics, predictors and outcomes among 99 patients hospitalised with COVID-19 in a tertiary care Centre in Switzerland: an observational analysis

Clinical features and outcomes of 98 patients hospitalized with SARS-CoV-2 infection in Daegu, South Korea: a brief descriptive study

Characteristics of patients with COVID-19 pneumonia at Hvidovre Hospital

Clinical characterization of 162 COVID-19 patients in Israel: preliminary report from a large tertiary center

Association of clinical and radiographic findings with the outcomes of 93 patients with COVID-19 in Wuhan

Epidemiological characteristics of coronavirus disease 2019 (COVID-19) patients in IRAN: a single center study

Characteristics, comorbidities, 30-day outcome and in-hospital mortality of patients hospitalised with COVID-19 in a Swiss area -a retrospective cohort study

Association of the insulin resistance marker TyG index with the severity and mortality of COVID-19

Association between chronic ACE inhibitor exposure and decreased odds of severe disease in patients with COVID-19

Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan

Identifying patients at greatest risk of mortality due to COVID-19: a New England perspective

Factors associated with the presence of headache in hospitalized COVID-19 patients and impact on prognosis: a retrospective cohort study

Coronavirus disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up

Risk factors for adverse clinical outcomes with COVID-19 in China: a multicenter, retrospective, observational study

Clinical characteristics and outcomes of patients with severe covid-19 with diabetes

Effect of hypertension on outcomes of adult inpatients with COVID-19 in Wuhan, China: a propensity score-matching analysis

Development and validation of a risk factor-based system to predict short-term survival in adult hospitalized patients with COVID-19: a multicenter, retrospective, cohort study

Clinical characteristics of different subtypes and risk factors for the severity of illness in patients with COVID-19 in Zhejiang, China

Clinical characteristics of patients with 2019 coronavirus disease in a non-Wuhan area of Hubei Province, China: a retrospective study

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

The clinical data from 19 critically ill patients with coronavirus disease 2019: a single-centered, retrospective, observational study

Cardiovascular implications of fatal outcomes of patients with Coronavirus Disease

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis

High prevalence of obesity in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation

Clinical features and treatment of COVID-19 patients in northeast Chongqing

Clinical findings of patients with coronavirus disease 2019 in Jiangsu province, China: a retrospective, multi-center study

Obesity and COVID-19 severity in a designated Hospital in Shenzhen

Associations of comorbidities and medications with COVID-19 outcome: a retrospective analysis of real-world evidence data

Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication

Metformin is associated with higher incidence of acidosis, but not mortality, in individuals with COVID-19 and pre-existing type 2 diabetes

Is there an association between metformin use and clinical outcomes in diabetes patients with COVID-19?

The clinical characteristics and outcomes of patients with moderate-to-severe coronavirus disease 2019 infection and diabetes in Daegu, South Korea

Metformin treatment was associated with decreased mortality in COVID-19 patients with diabetes in a retrospective analysis

Exposure to dipeptidylpeptidase-4 inhibitors and COVID-19 among people with type 2 diabetes: a case-control study

Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State

SARS-CoV-2 in Spanish Intensive Care Units: early experience with 15-day survival in Vitoria

Clinical features and short-term outcomes of 102 patients with coronavirus disease 2019 in Wuhan, China

Clinical characteristics and outcomes of older patients with coronavirus disease

China: a single-centered, retrospective study

Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 -United States

COVID-19 with different severities: a multicenter study of clinical features

Diabetes is a risk factor for the progression and prognosis of COVID-19

Analysis of epidemiological and clinical features in older patients with Coronavirus Disease 2019 (COVID-19) outside Wuhan

Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicentre) and outside Hubei (non-epicentre): a nationwide analysis of China

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area

Coronavirus Disease 19 infection does not result in acute kidney injury: an analysis of 116 hospitalized patients from Wuhan, China

Clinical characteristics of noncritically ill patients with novel coronavirus infection (COVID-19) in a Fangcang hospital

A retrospective study of risk factors for severe acute respiratory syndrome coronavirus 2 infections in hospitalized adult patients

Mortality rate and predictors of mortality in hospitalized COVID-19 patients with diabetes

Characteristics and outcomes of COVID-19 in hospitalized patients with and without diabetes

Characteristics of patients with diabetes hospitalised for COVID-19 infection-a brief case series report

The relationship between diabetes and clinical outcomes in COVID-19: a single-center retrospective analysis

The relationship between diabetes mellitus and COVID-19 prognosis: a retrospective cohort study in Wuhan, China

Prevalence, clinical manifestations, and biochemical data of type 2 diabetes mellitus versus nondiabetic symptomatic patients with COVID-19: a comparative study

The impact of type 2 diabetes and its management on the prognosis of patients with severe COVID-19

Metformin use is associated with reduced mortality in a diverse popularion with Covid-19 and diabetes. medRxiv

Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States

COVID-19 in a designated infectious diseases hospital outside Hubei Province

Clinical characteristics of 145 patients with corona virus disease 2019 (COVID-19

Clinical characteristics and risk factors for mortality of COVID-19 patients with diabetes in Wuhan, China: a two-center retrospective study

Clinical characteristics of 28 patients with diabetes and COVID-19 in Wuhan

Predicting mortality due to SARS-CoV-2: a mechanistic score relating obesity and diabetes to COVID-19 outcomes in Mexico

Baseline characteristics and risk factors for short-term outcomes in 132 COVID-19 patients with diabetes in Wuhan China: a retrospective study

The association of diabetes and the prognosis of COVID-19 patients: a retrospective study

Risk and predictors of inhospital mortality from COVID-19 in patients with diabetes and cardiovascular disease

Diabetes as a risk factor for poor early outcomes in patients hospitalized with COVID-19

Clinical and immunological features of severe and moderate coronavirus disease 2019

Risk factors of fatal outcome in hospitalized subjects with coronavirus disease 2019 from a Nationwide analysis in China

Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019

Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China

Characteristics of hospitalized adults with COVID-19 in an integrated health care system in California

Patients with diabetes are at higher risk for severe illness from COVID-19

Characteristics and clinical outcomes of adult patients hospitalized with Covid-19 -Georgia

Characteristics and outcomes of coronavirus disease patients under nonsurge conditions

Characteristics of Emergency Department patients with COVID-19 at a single site in Northern California: clinical observations and public health implications

Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China

Epidemiological and clinical features of 2019 novel coronavirus diseases (COVID-19) in the south of Iran

Clinical and laboratory findings from patients with COVID-19 pneumonia in Babol North of Iran: a retrospective cohort study

Clinical characteristics and outcome of hospitalized COVID-19 patients with diabetes: a single-center, retrospective study in Iran

Mortality risk factors among hospitalized COVID-19 patients in a major referral Center in Iran

Epidemiologic and clinical characteristics of 186 hospitalized patients with Covid-19 in Tehran, Iran: a retrospective, single-center case series

Risk indicators associated with in-hospital mortality and severity in patients with diabetes mellitus and confirmed or clinically suspected COVID-19

Characteristics and outcomes of a cohort of SARS-CoV-2 patients in the Province of Reggio Emilia

A cohort of patients with COVID-19 in a major teaching hospital in Europe

Clinical characteristics and predictors of outcomes of hospitalized patients with coronavirus disease 2019 in a multiethnic London National Health Service Trust: a retrospective cohort study

Development and validation of a survival calculator for hospitalized patients with

Analysis of hospitalized COVID-19 patients in the Mount Sinai Health System using electronic medical records (EMR) reveals important prognostic factors for improved clinical outcomes

Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. medRxiv

Clinical characteristics and outcomes of COVID-19 hospitalized patients with diabetes in the United Kingdom: a retrospective single Centre study

Features of 20 133 UKpatients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study

Early predictors of clinical outcomes of COVID-19 outbreak in

Risk factors for mortality and respiratory support in elderly patients hospitalized with COVID-19 in Korea

A retrospective analysis of the clinical and epidemiological characteristics of COVID-19 patients in Henan provincial People's hospital

Clinical characteristics and outcomes of the first 63 adult patients hospitalized with COVID-19: an experience from Oman

Characteristics and outcomes of COVID-19 patients in New York City's Public Hospital System

Risk factors for disease progression in patients with mild to moderate coronavirus disease 2019-a multi-Centre observational study

Prognostic factors for severe coronavirus disease 2019 in Daegu

Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan

Risk factors associated with clinical outcomes in 323 coronavirus disease 2019 (COVID-19) hospitalized patients in Wuhan, China

Analysis of the clinical characteristics, drug treatments and prognoses of 136 patients with coronavirus disease 2019

Epidemiological and clinical features of 200 hospitalized patients with corona virus disease 2019 outside Wuhan, China: a descriptive study

Clinical characteristics and risk factors for mortality among inpatients with COVID-19 in Wuhan, China

Clinical characteristics of Coronavirus Disease

Clinical characteristics of patients infected with the Novel 2019 Coronavirus (SARS-Cov-2) in Guangzhou

Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab

A cohort study of 223 patients explores the clinical risk factors for the severity diagnosis of COVID-19

A new predictor of disease severity in patients with COVID-19 in Wuhan, China

Characteristics of patients with COVID-19 during epidemic ongoing outbreak in Wuhan, China

Clinical characteristics of Coronavirus Disease 2019 (COVID-19) patients in Kuwait

Clinical characteristics of Coronavirus Disease

Clinical characteristics of hospitalized Covid-19 patients in New York City. medRxiv: the Preprint Server for Health Sciences

Clinical characteristics of imported and second-generation coronavirus disease 2019 (COVID-19) cases in Shaanxi outside Wuhan, China: a multicentre retrospective study

Clinical predictors of COVID-19 mortality. medRxiv: The Preprint Server for Health Sciences

Epidemiological and clinical features of 291 cases with coronavirus disease 2019 in areas adjacent to Hubei, China: a double-center observational study

Epidemiological and clinical features of 2019-nCoV acute respiratory disease cases in Chongqing municipality, China: a retrospective, descriptive, multiple-center study

Influence factors of death risk among COVID-19 patients in Wuhan, China: a hospital-based case-cohort study

Metabolic disturbances and inflammatory dysfunction predict severity of coronavirus disease 2019 (COVID-19): a retrospective study

Myocardial injury is associated with inhospital mortality of confirmed or suspected COVID-19 in Wuhan, China: a single center retrospective cohort study

Potential factors for prediction of disease severity of COVID-19 patients

Prognostic factors in spanish COVID-19 patients: a case series from barcelona

Progression, recovery and fatality in patients with SARS-CoV-2 related pneumonia in Wuhan, China: a singlecentered, retrospective, observational study

The characteristics and death risk factors of 132 COVID-19 pneumonia patients with comorbidities: a retrospective single center analysis in Wuhan, China

Comorbid diabetes mellitus was associated with poorer prognosis in patients with COVID-19: a retrospective cohort study

Comparable COVID-19 outcomes with current use of GLP-1 receptor agonists, DPP-4 inhibitors or SGLT-2 inhibitors among patients with diabetes who tested positive for SARS-CoV-2

Association between DPP-4 inhibitors and COVID-19-related outcomes among patients with type 2 diabetes

Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study

Are diabetes and its medications risk factors for the development of COVID-19? Data from a population-based study in Sicily

Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: updated results from the nationwide CORONADO study

No significant association between dipeptidyl peptidase-4 inhibitors and adverse outcomes of COVID-19

Insulin treatment is associated with increased mortality in patients with COVID-19 and type 2 diabetes

Insulin use, diabetes control, and outcomes in patients with COVID-19

Comparison of Mortality Rate and Severity of Pulmonary Involvement in Coronavirus Disease-2019 Adult Patients With and Without Type 2 Diabetes: A Cohort Study

Risk factors for severe illness in hospitalized Covid-19 patients at a regional hospital

Role of drugs used for chronic disease management on susceptibility and severity of COVID-19: a large case-control study

Predictors of adverse in-hospital outcome and recovery in patients with diabetes mellitus and COVID-19 pneumonia in Iraq

Metformin is associated with decreased 30-day mortality among nursing home residents infected with SARS-CoV2

Clinical findings in diabetes mellitus patients with COVID-19

Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes

Observational study of metformin and risk of mortality in patients hospitalized with Covid-19. medRxiv: The Preprint Server for Health Sciences

Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study

Association between diabetes and COVID-19: a retrospective observational study with a large sample of 1,880 cases in Leishenshan Hospital

Statin use and in-hospital mortality in patients with diabetes mellitus and COVID-19

Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality

Clinical characteristics, associated factors, and predicting COVID-19 mortality risk: a retrospective study in Wuhan, China

Association of diabetes mellitus with disease severity and prognosis in COVID-19: a retrospective cohort study

Impact of comorbidities and Glycemia at admission and Dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes with COVID-19: a case series from an academic Hospital in Lombardy

Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes

Can COVID-19 cause diabetes?

Clinical characteristics and outcomes of patients hospitalized with COVID-19 in Brazil: results from the Brazilian COVID-19 registry

International Diabetes Federation

Mortality and clinical outcomes in patients with COVID-19 pneumonia treated with non-invasive respiratory support: a rapid review

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement